BR116 / BRL Medicine - LARVOL DELTA

BR116: An antibody drug conjugate targeting CDH17 for gastrointestinal cancer therapy (AACR 2025) - "With its enhanced safety profile and promising efficacy, BR116 holds significant potential for further clinical development. BR116 is aiming to file for an IND in 2025."

Biliary Cancer • Cholangiocarcinoma • Colon Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CDH1 • CDH17 • CDH2 • CDH3 • CDH5